Review




Structured Review

Johns Hopkins HealthCare pk9 cells
Nicotine induces OPN accumulation in cultured PDA cells. AsPC-1 (A), Hs766T (B), and <t>PK9</t> (C) cells were treated with nicotine (3×10−9 – 3×10−7 mol/L) for 24 and 72 hr. Significant induction of OPN mRNA expression is seen with the maximum induction after 24 hr at 3×10−8 mol/L of nicotine.
Pk9 Cells, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/kpc+cells/pmc04465299-59-2-11
Average 90 stars, based on 1 article reviews
pk9 cells - by Bioz Stars, 2026-11
90/100 stars

Images

1) Product Images from "Induction of Osteopontin Expression by Nicotine and Cigarette Smoke in the Pancreas and Pancreatic Ductal Adenocarcinoma Cells"

Article Title: Induction of Osteopontin Expression by Nicotine and Cigarette Smoke in the Pancreas and Pancreatic Ductal Adenocarcinoma Cells

Journal: International journal of cancer. Journal international du cancer

doi: 10.1002/ijc.24388

Nicotine induces OPN accumulation in cultured PDA cells. AsPC-1 (A), Hs766T (B), and PK9 (C) cells were treated with nicotine (3×10−9 – 3×10−7 mol/L) for 24 and 72 hr. Significant induction of OPN mRNA expression is seen with the maximum induction after 24 hr at 3×10−8 mol/L of nicotine.
Figure Legend Snippet: Nicotine induces OPN accumulation in cultured PDA cells. AsPC-1 (A), Hs766T (B), and PK9 (C) cells were treated with nicotine (3×10−9 – 3×10−7 mol/L) for 24 and 72 hr. Significant induction of OPN mRNA expression is seen with the maximum induction after 24 hr at 3×10−8 mol/L of nicotine.

Techniques Used: Cell Culture, Expressing

Related Articles

Derivative Assay:

Article Title: Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy
Article Snippet: .. Two mouse tumor cell lines were used for implanted mouse tumor models: The KPC cell line, which is derived from LSL-Kras G12D/+ ; LSL-Trp53 R172H/+ ; Pdx-1-Cre (KPC) transgenic mice, was obtained from L. Zheng’s laboratory at the Johns Hopkins University ( 34 ); B16 melanoma was originally obtained from the American Type Culture Collection. ..

Transgenic Assay:

Article Title: Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy
Article Snippet: .. Two mouse tumor cell lines were used for implanted mouse tumor models: The KPC cell line, which is derived from LSL-Kras G12D/+ ; LSL-Trp53 R172H/+ ; Pdx-1-Cre (KPC) transgenic mice, was obtained from L. Zheng’s laboratory at the Johns Hopkins University ( 34 ); B16 melanoma was originally obtained from the American Type Culture Collection. ..

Generated:

Article Title: Gemcitabine Alters Phosphatidylcholine Metabolism in Mouse Pancreatic Tumors.
Article Snippet: Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest diseases, despite advancements in elucidating tumor biology and developing novel therapeutics.. Importantly, lipids, such as phospholipids, are crucial for the survival and proliferation of tumor cells.. However, the impact of chemotherapeutic drugs on phospholipid metabolism in PDAC remains poorly understood.

Article Title: Exosomal miRNA 16-5p/29a-3p from pancreatic cancer induce adipose atrophy by inhibiting adipogenesis and promoting lipolysis
Article Snippet: .. KPC cells were obtained from Dr. Lei Zheng (Johns Hopkins University School of Medicine) and generated from the primary pancreas site of Pdx1 - Cre ; LSL - Kras G12D/+ ; Trp53 R172H/+ male mice. .. Pan18 cells were cultured with high-glucose-DMEM (Cat: 11965-092, Gibco).

Transplantation Assay:

Article Title: Gemcitabine Alters Phosphatidylcholine Metabolism in Mouse Pancreatic Tumors.
Article Snippet: Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest diseases, despite advancements in elucidating tumor biology and developing novel therapeutics.. Importantly, lipids, such as phospholipids, are crucial for the survival and proliferation of tumor cells.. However, the impact of chemotherapeutic drugs on phospholipid metabolism in PDAC remains poorly understood.

Injection:

Article Title: Gemcitabine Alters Phosphatidylcholine Metabolism in Mouse Pancreatic Tumors.
Article Snippet: Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest diseases, despite advancements in elucidating tumor biology and developing novel therapeutics.. Importantly, lipids, such as phospholipids, are crucial for the survival and proliferation of tumor cells.. However, the impact of chemotherapeutic drugs on phospholipid metabolism in PDAC remains poorly understood.

other:

Article Title: Compartmentalized role of xCT in supporting pancreatic tumor growth, inflammation and mood disturbance in mice.
Article Snippet: Panc02 cells (gift from Dr. C. Gravekamp, Albert Einstein College of Medicine, New York, USA (Chandra et al., 2017)) and KPC cells (gift from Dr. E. Jaffee, Johns Hopkins University, Baltimore, USA (Foley et al., 2015)) were maintained in supplemented culture medium (RPMI 1640 + L-glutamine, supplemented with 10 % Fetal Bovine Serum, 1 % Penicillin/Streptomycin, 1 % Sodium Pyruvate and 1 % Minimum Essential Medium Non-Essential Amino Acids; all from Thermo Fisher Scientific), in a humidified atmosphere at 37 ◦C and 5 % CO2.

Article Title: Tumor Microenvironment Responsive CD8 + T Cells and Myeloid‐Derived Suppressor Cells to Trigger CD73 Inhibitor AB680‐Based Synergistic Therapy for Pancreatic Cancer
Article Snippet: Mouse‐derived PC cell lines Panc02 cells and LSL‐K‐ras G12D/+ ; Trp53 R172H/+ ; Pdx‐1 Cre/+ (KPC) cells were kind gifts from Johns Hopkins Hospital.

Article Title: UBR2 targets myosin heavy chain IIb and IIx for degradation: Molecular mechanism essential for cancer-induced muscle wasting
Article Snippet: Tumor cell lines, including LLC, C26 (National Cancer Institute), H1299, BxPC-3 (American Type Culture Collection [ATCC]), and KPC (a gift from Elizabeth Jaffee, Johns Hopkins University, Baltimore, MD) ( ) were cultured in RPMI1640 supplemented with 10% FBS.

Article Title: Tumor Microenvironment Responsive CD8 + T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Cancer.
Article Snippet: Mousederived PC cell lines Panc02 cells and LSL-K-rasG12D/+; Trp53R172H/+; Pdx1Cre/+ (KPC) cells were kind gifts from Johns Hopkins Hospital.



Similar Products

99
CancerTools Org kpc cells
Kpc Cells, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/KPC+-+C57%2FBL6+background/pm42971279-99-0-20
Average 99 stars, based on 1 article reviews
kpc cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
CancerTools Org kpc cells are also available for purchase from
Kpc Cells Are Also Available For Purchase From, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/KPC+-+C57%2FBL6+background/pmc13675828-26-15-23
Average 99 stars, based on 1 article reviews
kpc cells are also available for purchase from - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC type culture collection tib 202 huvec american type culture collection pcs 100 013 hpde6 c7 anwei sci cell center aw ch0777 kpc 0116 fuscc
Type Culture Collection Tib 202 Huvec American Type Culture Collection Pcs 100 013 Hpde6 C7 Anwei Sci Cell Center Aw Ch0777 Kpc 0116 Fuscc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human%2C+Pooled/pm42276047-732-169-174
Average 99 stars, based on 1 article reviews
type culture collection tib 202 huvec american type culture collection pcs 100 013 hpde6 c7 anwei sci cell center aw ch0777 kpc 0116 fuscc - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

86
Jackson Laboratory kpc cells
CO exposure increases MHC-I and PD-L1 expression in pancreatic cancer cells. Human and mouse pancreatic cancer cell lines were exposed to CO in the air at a concentration of 250 ppm for 48 hours before being harvested for analysis of gene and protein expression. (A) Log 10 -fold change in RNA levels for antigen processing and presentation proteins, MHC-I molecules, and PD-L1 in human pancreatic cancer cells (Panc1) exposed to CO relative to air. Data are means ± standard deviation. CO-treated samples; n=3; air-treated samples, n=3. (B) Gene set enrichment analysis of pathways that promote immunotherapy response and were upregulated in human pancreatic cancer cells (Panc1) exposed to CO relative to those exposed to air. Data are means ± standard deviation; CO-treated samples; n=3; air-treated samples, n=3. (C) Western blots from cell lysates obtained from human pancreatic cancer cells (Panc1) or mouse pancreatic cancer cells <t>(KPC)</t> exposed to CO or air. β-actin served as a loading control. (D) Flow cytometric analysis of Panc1 or <t>KPC</t> <t>cells</t> exposed to CO or air in the presence or absence of increasing concentrations of IFN-γ. Cells were analyzed for expression of MHC-I (HLA in humans; H2Kb in mice) or PD-L1. Results represent the mean ± standard deviation of 3 independent experiments. *, P<0.05; **, P<0.01; ***, P < 0.001; Panc1 with CO + IFN-γ, n=8; Panc1 with air + IFN-γ, n=8; KPC with CO + IFN-γ, n=8; KPC with air + IFN-γ, n=8; P values were determined by unpaired t-test.
Kpc Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/cells+derived+mnp+primary/pmc11788032-91-8-19
Average 86 stars, based on 1 article reviews
kpc cells - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

97
MedChemExpress kpc cells
A Cellular proportions of each TMS subtype, with immune cells and fibroblast fractions shown (mean ± SD, N = 148/116/196, p < 0.0001). B Venn diagram of intersecting metabolic features from metabolomic and transcriptomic analyses. C Ferroptosis-associated metabolic fluxes, pathways ( N = 148/312), and metabolites ( N = 75/115) between TMS1 and non-TMS1 (median, 25th–75th percentiles). D Enrichment of glutathione metabolism genes in TMS1 PDACs. E GSH/GSSG ratios between TMS1 ( N = 75) and non-TMS1 ( N = 115) PDACs (mean, 95% CI, p < 0.0001). F Normalized scores for glutathione, BH4, complex I-IV, CoQ10, fatty acids, and membrane lipids between TMS1 ( N = 148) and non-TMS1 ( N = 312) PDAC subtypes (mean ± SD). G GSH/GSSG ratios in organoids from TMS1 and non-TMS1 PDACs (mean ± SD, n = 3, biological replicates, p < 0.0001). Heatmap of fold change in MDA concentration before and after RSL-3 treatment. H Drug sensitivity (relative IC50) of five common PDAC chemotherapy regimens for TMS1 and non-TMS1 subtypes. I Workflow for calculating drug sensitivity using snRNA-seq data. Relative IC50 values for drugs in TMS1 ( N = 4) vs non-TMS1 PDAC cells ( N = 5). J Workflow for generating <t>drug-resistant</t> <t>MIA</t> PaCa-2 and <t>KPC-0116</t> cells and comparing IC50 ratios to their parental cells. K GPX4 expression in resistant vs parental cells (loading control: β-actin). L Deregulation of ferroptosis-related proteins in chemotherapy-treated PDACs. M Workflow for generating PDPPCs (patient-derived primary PDAC cells) and drug sensitivity testing. N Synergy scores (ZIP method, mean ± SD, two-sided) for RSL-3 plus paclitaxel in TMS1 ( N = 7) and non-TMS1 ( N = 16) PDPPCs. O Bright-field image and viability curve of RSL-3 (100 nM) plus paclitaxel (2 nM) in TMS1 and non-TMS1 organoids ( n = 3, biological replicates, mean ± SD, p = 0.005, p = 0.002). P Tumor size change (CT imaging) in a PDAC patient, during AG regimen treatment (maximum diameter ratios, p < 0.0001). Q Bright-field images and viability of organoids treated with paclitaxel and/or RSL-3 ( n = 3, biological replicates, mean ± SD). Significance was determined by the two-sided Wilcoxon test ( C , E , F , I ), Kruskal–Wallis test ( A ), two-sided unpaired t -test ( G , N , H , L , O ), and the one-way ANOVA with Tukey’s multiple comparisons test ( Q ). Source data are provided as a Source Data file.
Kpc Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/Gemcitabine/pmc13391501-465-9-20
Average 97 stars, based on 1 article reviews
kpc cells - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

86
Pharmatech 105 kpc cells
A Cellular proportions of each TMS subtype, with immune cells and fibroblast fractions shown (mean ± SD, N = 148/116/196, p < 0.0001). B Venn diagram of intersecting metabolic features from metabolomic and transcriptomic analyses. C Ferroptosis-associated metabolic fluxes, pathways ( N = 148/312), and metabolites ( N = 75/115) between TMS1 and non-TMS1 (median, 25th–75th percentiles). D Enrichment of glutathione metabolism genes in TMS1 PDACs. E GSH/GSSG ratios between TMS1 ( N = 75) and non-TMS1 ( N = 115) PDACs (mean, 95% CI, p < 0.0001). F Normalized scores for glutathione, BH4, complex I-IV, CoQ10, fatty acids, and membrane lipids between TMS1 ( N = 148) and non-TMS1 ( N = 312) PDAC subtypes (mean ± SD). G GSH/GSSG ratios in organoids from TMS1 and non-TMS1 PDACs (mean ± SD, n = 3, biological replicates, p < 0.0001). Heatmap of fold change in MDA concentration before and after RSL-3 treatment. H Drug sensitivity (relative IC50) of five common PDAC chemotherapy regimens for TMS1 and non-TMS1 subtypes. I Workflow for calculating drug sensitivity using snRNA-seq data. Relative IC50 values for drugs in TMS1 ( N = 4) vs non-TMS1 PDAC cells ( N = 5). J Workflow for generating <t>drug-resistant</t> <t>MIA</t> PaCa-2 and <t>KPC-0116</t> cells and comparing IC50 ratios to their parental cells. K GPX4 expression in resistant vs parental cells (loading control: β-actin). L Deregulation of ferroptosis-related proteins in chemotherapy-treated PDACs. M Workflow for generating PDPPCs (patient-derived primary PDAC cells) and drug sensitivity testing. N Synergy scores (ZIP method, mean ± SD, two-sided) for RSL-3 plus paclitaxel in TMS1 ( N = 7) and non-TMS1 ( N = 16) PDPPCs. O Bright-field image and viability curve of RSL-3 (100 nM) plus paclitaxel (2 nM) in TMS1 and non-TMS1 organoids ( n = 3, biological replicates, mean ± SD, p = 0.005, p = 0.002). P Tumor size change (CT imaging) in a PDAC patient, during AG regimen treatment (maximum diameter ratios, p < 0.0001). Q Bright-field images and viability of organoids treated with paclitaxel and/or RSL-3 ( n = 3, biological replicates, mean ± SD). Significance was determined by the two-sided Wilcoxon test ( C , E , F , I ), Kruskal–Wallis test ( A ), two-sided unpaired t -test ( G , N , H , L , O ), and the one-way ANOVA with Tukey’s multiple comparisons test ( Q ). Source data are provided as a Source Data file.
105 Kpc Cells, supplied by Pharmatech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/105+cells+kpc/pm42098409-93-15-7
Average 86 stars, based on 1 article reviews
105 kpc cells - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Shanghai Model Organisms Center kpc mouse pancreatic cancer cells
A Cellular proportions of each TMS subtype, with immune cells and fibroblast fractions shown (mean ± SD, N = 148/116/196, p < 0.0001). B Venn diagram of intersecting metabolic features from metabolomic and transcriptomic analyses. C Ferroptosis-associated metabolic fluxes, pathways ( N = 148/312), and metabolites ( N = 75/115) between TMS1 and non-TMS1 (median, 25th–75th percentiles). D Enrichment of glutathione metabolism genes in TMS1 PDACs. E GSH/GSSG ratios between TMS1 ( N = 75) and non-TMS1 ( N = 115) PDACs (mean, 95% CI, p < 0.0001). F Normalized scores for glutathione, BH4, complex I-IV, CoQ10, fatty acids, and membrane lipids between TMS1 ( N = 148) and non-TMS1 ( N = 312) PDAC subtypes (mean ± SD). G GSH/GSSG ratios in organoids from TMS1 and non-TMS1 PDACs (mean ± SD, n = 3, biological replicates, p < 0.0001). Heatmap of fold change in MDA concentration before and after RSL-3 treatment. H Drug sensitivity (relative IC50) of five common PDAC chemotherapy regimens for TMS1 and non-TMS1 subtypes. I Workflow for calculating drug sensitivity using snRNA-seq data. Relative IC50 values for drugs in TMS1 ( N = 4) vs non-TMS1 PDAC cells ( N = 5). J Workflow for generating <t>drug-resistant</t> <t>MIA</t> PaCa-2 and <t>KPC-0116</t> cells and comparing IC50 ratios to their parental cells. K GPX4 expression in resistant vs parental cells (loading control: β-actin). L Deregulation of ferroptosis-related proteins in chemotherapy-treated PDACs. M Workflow for generating PDPPCs (patient-derived primary PDAC cells) and drug sensitivity testing. N Synergy scores (ZIP method, mean ± SD, two-sided) for RSL-3 plus paclitaxel in TMS1 ( N = 7) and non-TMS1 ( N = 16) PDPPCs. O Bright-field image and viability curve of RSL-3 (100 nM) plus paclitaxel (2 nM) in TMS1 and non-TMS1 organoids ( n = 3, biological replicates, mean ± SD, p = 0.005, p = 0.002). P Tumor size change (CT imaging) in a PDAC patient, during AG regimen treatment (maximum diameter ratios, p < 0.0001). Q Bright-field images and viability of organoids treated with paclitaxel and/or RSL-3 ( n = 3, biological replicates, mean ± SD). Significance was determined by the two-sided Wilcoxon test ( C , E , F , I ), Kruskal–Wallis test ( A ), two-sided unpaired t -test ( G , N , H , L , O ), and the one-way ANOVA with Tukey’s multiple comparisons test ( Q ). Source data are provided as a Source Data file.
Kpc Mouse Pancreatic Cancer Cells, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/cardiomyocyte+fto+knockout+mice+specific/pmc13130681-67-0-6
Average 86 stars, based on 1 article reviews
kpc mouse pancreatic cancer cells - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Shanghai Model Organisms Center kpc cells
A Cellular proportions of each TMS subtype, with immune cells and fibroblast fractions shown (mean ± SD, N = 148/116/196, p < 0.0001). B Venn diagram of intersecting metabolic features from metabolomic and transcriptomic analyses. C Ferroptosis-associated metabolic fluxes, pathways ( N = 148/312), and metabolites ( N = 75/115) between TMS1 and non-TMS1 (median, 25th–75th percentiles). D Enrichment of glutathione metabolism genes in TMS1 PDACs. E GSH/GSSG ratios between TMS1 ( N = 75) and non-TMS1 ( N = 115) PDACs (mean, 95% CI, p < 0.0001). F Normalized scores for glutathione, BH4, complex I-IV, CoQ10, fatty acids, and membrane lipids between TMS1 ( N = 148) and non-TMS1 ( N = 312) PDAC subtypes (mean ± SD). G GSH/GSSG ratios in organoids from TMS1 and non-TMS1 PDACs (mean ± SD, n = 3, biological replicates, p < 0.0001). Heatmap of fold change in MDA concentration before and after RSL-3 treatment. H Drug sensitivity (relative IC50) of five common PDAC chemotherapy regimens for TMS1 and non-TMS1 subtypes. I Workflow for calculating drug sensitivity using snRNA-seq data. Relative IC50 values for drugs in TMS1 ( N = 4) vs non-TMS1 PDAC cells ( N = 5). J Workflow for generating <t>drug-resistant</t> <t>MIA</t> PaCa-2 and <t>KPC-0116</t> cells and comparing IC50 ratios to their parental cells. K GPX4 expression in resistant vs parental cells (loading control: β-actin). L Deregulation of ferroptosis-related proteins in chemotherapy-treated PDACs. M Workflow for generating PDPPCs (patient-derived primary PDAC cells) and drug sensitivity testing. N Synergy scores (ZIP method, mean ± SD, two-sided) for RSL-3 plus paclitaxel in TMS1 ( N = 7) and non-TMS1 ( N = 16) PDPPCs. O Bright-field image and viability curve of RSL-3 (100 nM) plus paclitaxel (2 nM) in TMS1 and non-TMS1 organoids ( n = 3, biological replicates, mean ± SD, p = 0.005, p = 0.002). P Tumor size change (CT imaging) in a PDAC patient, during AG regimen treatment (maximum diameter ratios, p < 0.0001). Q Bright-field images and viability of organoids treated with paclitaxel and/or RSL-3 ( n = 3, biological replicates, mean ± SD). Significance was determined by the two-sided Wilcoxon test ( C , E , F , I ), Kruskal–Wallis test ( A ), two-sided unpaired t -test ( G , N , H , L , O ), and the one-way ANOVA with Tukey’s multiple comparisons test ( Q ). Source data are provided as a Source Data file.
Kpc Cells, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/cell+kpc+line/pmc13191904-76-17-22
Average 86 stars, based on 1 article reviews
kpc cells - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Shanghai Model Organisms Center s13 kpc mouse pancreatic cancer cells shanghai model organisms center
A Cellular proportions of each TMS subtype, with immune cells and fibroblast fractions shown (mean ± SD, N = 148/116/196, p < 0.0001). B Venn diagram of intersecting metabolic features from metabolomic and transcriptomic analyses. C Ferroptosis-associated metabolic fluxes, pathways ( N = 148/312), and metabolites ( N = 75/115) between TMS1 and non-TMS1 (median, 25th–75th percentiles). D Enrichment of glutathione metabolism genes in TMS1 PDACs. E GSH/GSSG ratios between TMS1 ( N = 75) and non-TMS1 ( N = 115) PDACs (mean, 95% CI, p < 0.0001). F Normalized scores for glutathione, BH4, complex I-IV, CoQ10, fatty acids, and membrane lipids between TMS1 ( N = 148) and non-TMS1 ( N = 312) PDAC subtypes (mean ± SD). G GSH/GSSG ratios in organoids from TMS1 and non-TMS1 PDACs (mean ± SD, n = 3, biological replicates, p < 0.0001). Heatmap of fold change in MDA concentration before and after RSL-3 treatment. H Drug sensitivity (relative IC50) of five common PDAC chemotherapy regimens for TMS1 and non-TMS1 subtypes. I Workflow for calculating drug sensitivity using snRNA-seq data. Relative IC50 values for drugs in TMS1 ( N = 4) vs non-TMS1 PDAC cells ( N = 5). J Workflow for generating <t>drug-resistant</t> <t>MIA</t> PaCa-2 and <t>KPC-0116</t> cells and comparing IC50 ratios to their parental cells. K GPX4 expression in resistant vs parental cells (loading control: β-actin). L Deregulation of ferroptosis-related proteins in chemotherapy-treated PDACs. M Workflow for generating PDPPCs (patient-derived primary PDAC cells) and drug sensitivity testing. N Synergy scores (ZIP method, mean ± SD, two-sided) for RSL-3 plus paclitaxel in TMS1 ( N = 7) and non-TMS1 ( N = 16) PDPPCs. O Bright-field image and viability curve of RSL-3 (100 nM) plus paclitaxel (2 nM) in TMS1 and non-TMS1 organoids ( n = 3, biological replicates, mean ± SD, p = 0.005, p = 0.002). P Tumor size change (CT imaging) in a PDAC patient, during AG regimen treatment (maximum diameter ratios, p < 0.0001). Q Bright-field images and viability of organoids treated with paclitaxel and/or RSL-3 ( n = 3, biological replicates, mean ± SD). Significance was determined by the two-sided Wilcoxon test ( C , E , F , I ), Kruskal–Wallis test ( A ), two-sided unpaired t -test ( G , N , H , L , O ), and the one-way ANOVA with Tukey’s multiple comparisons test ( Q ). Source data are provided as a Source Data file.
S13 Kpc Mouse Pancreatic Cancer Cells Shanghai Model Organisms Center, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/cardiomyocyte+fto+knockout+mice+specific/pm41895288-259-169-175
Average 86 stars, based on 1 article reviews
s13 kpc mouse pancreatic cancer cells shanghai model organisms center - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


CO exposure increases MHC-I and PD-L1 expression in pancreatic cancer cells. Human and mouse pancreatic cancer cell lines were exposed to CO in the air at a concentration of 250 ppm for 48 hours before being harvested for analysis of gene and protein expression. (A) Log 10 -fold change in RNA levels for antigen processing and presentation proteins, MHC-I molecules, and PD-L1 in human pancreatic cancer cells (Panc1) exposed to CO relative to air. Data are means ± standard deviation. CO-treated samples; n=3; air-treated samples, n=3. (B) Gene set enrichment analysis of pathways that promote immunotherapy response and were upregulated in human pancreatic cancer cells (Panc1) exposed to CO relative to those exposed to air. Data are means ± standard deviation; CO-treated samples; n=3; air-treated samples, n=3. (C) Western blots from cell lysates obtained from human pancreatic cancer cells (Panc1) or mouse pancreatic cancer cells (KPC) exposed to CO or air. β-actin served as a loading control. (D) Flow cytometric analysis of Panc1 or KPC cells exposed to CO or air in the presence or absence of increasing concentrations of IFN-γ. Cells were analyzed for expression of MHC-I (HLA in humans; H2Kb in mice) or PD-L1. Results represent the mean ± standard deviation of 3 independent experiments. *, P<0.05; **, P<0.01; ***, P < 0.001; Panc1 with CO + IFN-γ, n=8; Panc1 with air + IFN-γ, n=8; KPC with CO + IFN-γ, n=8; KPC with air + IFN-γ, n=8; P values were determined by unpaired t-test.

Journal: Biomaterials

Article Title: Potentiating the effect of immunotherapy in pancreatic cancer using gas-entrapping materials

doi: 10.1016/j.biomaterials.2025.123097

Figure Lengend Snippet: CO exposure increases MHC-I and PD-L1 expression in pancreatic cancer cells. Human and mouse pancreatic cancer cell lines were exposed to CO in the air at a concentration of 250 ppm for 48 hours before being harvested for analysis of gene and protein expression. (A) Log 10 -fold change in RNA levels for antigen processing and presentation proteins, MHC-I molecules, and PD-L1 in human pancreatic cancer cells (Panc1) exposed to CO relative to air. Data are means ± standard deviation. CO-treated samples; n=3; air-treated samples, n=3. (B) Gene set enrichment analysis of pathways that promote immunotherapy response and were upregulated in human pancreatic cancer cells (Panc1) exposed to CO relative to those exposed to air. Data are means ± standard deviation; CO-treated samples; n=3; air-treated samples, n=3. (C) Western blots from cell lysates obtained from human pancreatic cancer cells (Panc1) or mouse pancreatic cancer cells (KPC) exposed to CO or air. β-actin served as a loading control. (D) Flow cytometric analysis of Panc1 or KPC cells exposed to CO or air in the presence or absence of increasing concentrations of IFN-γ. Cells were analyzed for expression of MHC-I (HLA in humans; H2Kb in mice) or PD-L1. Results represent the mean ± standard deviation of 3 independent experiments. *, P<0.05; **, P<0.01; ***, P < 0.001; Panc1 with CO + IFN-γ, n=8; Panc1 with air + IFN-γ, n=8; KPC with CO + IFN-γ, n=8; KPC with air + IFN-γ, n=8; P values were determined by unpaired t-test.

Article Snippet: To generate syngeneic tumors, 3 × 10 6 KPC cells were injected into the right flank of C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, USA).

Techniques: Expressing, Concentration Assay, Standard Deviation, Western Blot, Control

Enhanced anti-tumor effects for combined treatment with CO-GeMs and ICIs. (A) Volumes and weights of subcutaneous allograft pancreatic tumors. Once tumors reached a volume of approximately 100 mm 3 mice received intratumoral injection of CO-GeMs and anti-PD-1 antibody, alone and in combination, or with IgG control. Results represent the mean ± standard deviation of 7 mice/group. Statistical analysis on day 19 post initiation of treatment. *, P<0.05; **, P<0.01; ***, P < 0.001; P values determined by one-way ANOVA. (B) Representative immunohistochemical staining for CD8 and CD45 in tumors treated with anti-PD-1 antibody with or without CO-GeM exposure in mice treated as in (A). (C) Quantification of CD8+ and CD45+ cells in subcutaneous allograft tumors from mice treated as in (A). The results represent the mean ± standard deviation of 10 images/group. NS, not significant; *, p < 0.05, ***, P <0.001. P values were determined by one-way ANOVA. (D) Luciferase emission as determined by bioluminescence imaging and Kaplan-Meier survival curves of allograft hepatic metastases induced in C57BL/6J mice using luc-expressing KPC cells. Results represent mean ± standard deviation of 5–7 mice/group. IgG control, n=5; CO, n=6; anti-PD-1, n=7; anti-PD-1 + CO, n=7. P values were determined by one-way ANOVA. NS, not significant; *, p < 0.05; **, p < 0.01.

Journal: Biomaterials

Article Title: Potentiating the effect of immunotherapy in pancreatic cancer using gas-entrapping materials

doi: 10.1016/j.biomaterials.2025.123097

Figure Lengend Snippet: Enhanced anti-tumor effects for combined treatment with CO-GeMs and ICIs. (A) Volumes and weights of subcutaneous allograft pancreatic tumors. Once tumors reached a volume of approximately 100 mm 3 mice received intratumoral injection of CO-GeMs and anti-PD-1 antibody, alone and in combination, or with IgG control. Results represent the mean ± standard deviation of 7 mice/group. Statistical analysis on day 19 post initiation of treatment. *, P<0.05; **, P<0.01; ***, P < 0.001; P values determined by one-way ANOVA. (B) Representative immunohistochemical staining for CD8 and CD45 in tumors treated with anti-PD-1 antibody with or without CO-GeM exposure in mice treated as in (A). (C) Quantification of CD8+ and CD45+ cells in subcutaneous allograft tumors from mice treated as in (A). The results represent the mean ± standard deviation of 10 images/group. NS, not significant; *, p < 0.05, ***, P <0.001. P values were determined by one-way ANOVA. (D) Luciferase emission as determined by bioluminescence imaging and Kaplan-Meier survival curves of allograft hepatic metastases induced in C57BL/6J mice using luc-expressing KPC cells. Results represent mean ± standard deviation of 5–7 mice/group. IgG control, n=5; CO, n=6; anti-PD-1, n=7; anti-PD-1 + CO, n=7. P values were determined by one-way ANOVA. NS, not significant; *, p < 0.05; **, p < 0.01.

Article Snippet: To generate syngeneic tumors, 3 × 10 6 KPC cells were injected into the right flank of C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, USA).

Techniques: Injection, Control, Standard Deviation, Immunohistochemical staining, Staining, Luciferase, Imaging, Expressing

A Cellular proportions of each TMS subtype, with immune cells and fibroblast fractions shown (mean ± SD, N = 148/116/196, p < 0.0001). B Venn diagram of intersecting metabolic features from metabolomic and transcriptomic analyses. C Ferroptosis-associated metabolic fluxes, pathways ( N = 148/312), and metabolites ( N = 75/115) between TMS1 and non-TMS1 (median, 25th–75th percentiles). D Enrichment of glutathione metabolism genes in TMS1 PDACs. E GSH/GSSG ratios between TMS1 ( N = 75) and non-TMS1 ( N = 115) PDACs (mean, 95% CI, p < 0.0001). F Normalized scores for glutathione, BH4, complex I-IV, CoQ10, fatty acids, and membrane lipids between TMS1 ( N = 148) and non-TMS1 ( N = 312) PDAC subtypes (mean ± SD). G GSH/GSSG ratios in organoids from TMS1 and non-TMS1 PDACs (mean ± SD, n = 3, biological replicates, p < 0.0001). Heatmap of fold change in MDA concentration before and after RSL-3 treatment. H Drug sensitivity (relative IC50) of five common PDAC chemotherapy regimens for TMS1 and non-TMS1 subtypes. I Workflow for calculating drug sensitivity using snRNA-seq data. Relative IC50 values for drugs in TMS1 ( N = 4) vs non-TMS1 PDAC cells ( N = 5). J Workflow for generating drug-resistant MIA PaCa-2 and KPC-0116 cells and comparing IC50 ratios to their parental cells. K GPX4 expression in resistant vs parental cells (loading control: β-actin). L Deregulation of ferroptosis-related proteins in chemotherapy-treated PDACs. M Workflow for generating PDPPCs (patient-derived primary PDAC cells) and drug sensitivity testing. N Synergy scores (ZIP method, mean ± SD, two-sided) for RSL-3 plus paclitaxel in TMS1 ( N = 7) and non-TMS1 ( N = 16) PDPPCs. O Bright-field image and viability curve of RSL-3 (100 nM) plus paclitaxel (2 nM) in TMS1 and non-TMS1 organoids ( n = 3, biological replicates, mean ± SD, p = 0.005, p = 0.002). P Tumor size change (CT imaging) in a PDAC patient, during AG regimen treatment (maximum diameter ratios, p < 0.0001). Q Bright-field images and viability of organoids treated with paclitaxel and/or RSL-3 ( n = 3, biological replicates, mean ± SD). Significance was determined by the two-sided Wilcoxon test ( C , E , F , I ), Kruskal–Wallis test ( A ), two-sided unpaired t -test ( G , N , H , L , O ), and the one-way ANOVA with Tukey’s multiple comparisons test ( Q ). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer

doi: 10.1038/s41467-026-73702-z

Figure Lengend Snippet: A Cellular proportions of each TMS subtype, with immune cells and fibroblast fractions shown (mean ± SD, N = 148/116/196, p < 0.0001). B Venn diagram of intersecting metabolic features from metabolomic and transcriptomic analyses. C Ferroptosis-associated metabolic fluxes, pathways ( N = 148/312), and metabolites ( N = 75/115) between TMS1 and non-TMS1 (median, 25th–75th percentiles). D Enrichment of glutathione metabolism genes in TMS1 PDACs. E GSH/GSSG ratios between TMS1 ( N = 75) and non-TMS1 ( N = 115) PDACs (mean, 95% CI, p < 0.0001). F Normalized scores for glutathione, BH4, complex I-IV, CoQ10, fatty acids, and membrane lipids between TMS1 ( N = 148) and non-TMS1 ( N = 312) PDAC subtypes (mean ± SD). G GSH/GSSG ratios in organoids from TMS1 and non-TMS1 PDACs (mean ± SD, n = 3, biological replicates, p < 0.0001). Heatmap of fold change in MDA concentration before and after RSL-3 treatment. H Drug sensitivity (relative IC50) of five common PDAC chemotherapy regimens for TMS1 and non-TMS1 subtypes. I Workflow for calculating drug sensitivity using snRNA-seq data. Relative IC50 values for drugs in TMS1 ( N = 4) vs non-TMS1 PDAC cells ( N = 5). J Workflow for generating drug-resistant MIA PaCa-2 and KPC-0116 cells and comparing IC50 ratios to their parental cells. K GPX4 expression in resistant vs parental cells (loading control: β-actin). L Deregulation of ferroptosis-related proteins in chemotherapy-treated PDACs. M Workflow for generating PDPPCs (patient-derived primary PDAC cells) and drug sensitivity testing. N Synergy scores (ZIP method, mean ± SD, two-sided) for RSL-3 plus paclitaxel in TMS1 ( N = 7) and non-TMS1 ( N = 16) PDPPCs. O Bright-field image and viability curve of RSL-3 (100 nM) plus paclitaxel (2 nM) in TMS1 and non-TMS1 organoids ( n = 3, biological replicates, mean ± SD, p = 0.005, p = 0.002). P Tumor size change (CT imaging) in a PDAC patient, during AG regimen treatment (maximum diameter ratios, p < 0.0001). Q Bright-field images and viability of organoids treated with paclitaxel and/or RSL-3 ( n = 3, biological replicates, mean ± SD). Significance was determined by the two-sided Wilcoxon test ( C , E , F , I ), Kruskal–Wallis test ( A ), two-sided unpaired t -test ( G , N , H , L , O ), and the one-way ANOVA with Tukey’s multiple comparisons test ( Q ). Source data are provided as a Source Data file.

Article Snippet: Drug-resistant cell lines were established from MIA PaCa-2 and KPC cells by gradually exposing them to increasing concentrations of gemcitabine (MCE, HY-17026), oxaliplatin (MCE, HY-17371), paclitaxel (MCE, HY-B0015), irinotecan (MCE, HY-16562), and 5-fluorouracil (MCE, HY-90006) .

Techniques: Metabolomic, Membrane, Concentration Assay, Expressing, Control, Derivative Assay, Imaging